These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
407 related items for PubMed ID: 27788026
1. Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Hershey AD, CHAMP Investigators. N Engl J Med; 2017 Jan 12; 376(2):115-124. PubMed ID: 27788026 [Abstract] [Full Text] [Related]
2. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, Biondi D, Greenberg SJ, Hulihan J, CAPSS-277 Investigator Group. Clin Ther; 2009 Mar 12; 31(3):542-59. PubMed ID: 19393844 [Abstract] [Full Text] [Related]
9. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Keskinbora K, Aydinli I. Clin Neurol Neurosurg; 2008 Dec 12; 110(10):979-84. PubMed ID: 18620801 [Abstract] [Full Text] [Related]
11. Impact of preventive pill-based treatment on migraine days: A secondary outcome study of the Childhood and Adolescent Migraine Prevention (CHAMP) trial and a comparison of self-report to nosology-derived assessments. Gibler RC, Peugh JL, Coffey CS, Chamberlin LA, Ecklund D, Klingner E, Yankey J, Korbee LL, Kabbouche M, Kacperski J, Porter LL, Reidy BL, Hershey AD, Powers SW. Headache; 2023 Jun 12; 63(6):805-812. PubMed ID: 36757131 [Abstract] [Full Text] [Related]
12. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Lewis D, Winner P, Saper J, Ness S, Polverejan E, Wang S, Kurland CL, Nye J, Yuen E, Eerdekens M, Ford L. Pediatrics; 2009 Mar 12; 123(3):924-34. PubMed ID: 19255022 [Abstract] [Full Text] [Related]
13. Time course of adverse events most commonly associated with topiramate for migraine prevention. Láinez MJ, Freitag FG, Pfeil J, Ascher S, Olson WH, Schwalen S. Eur J Neurol; 2007 Aug 12; 14(8):900-6. PubMed ID: 17662012 [Abstract] [Full Text] [Related]
14. Topiramate in migraine prevention: results of a large controlled trial. Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group. Arch Neurol; 2004 Apr 12; 61(4):490-5. PubMed ID: 15096395 [Abstract] [Full Text] [Related]
15. Long-term migraine prevention with topiramate: open-label extension of pivotal trials. Rapoport A, Mauskop A, Diener HC, Schwalen S, Pfeil J. Headache; 2006 Apr 12; 46(7):1151-60. PubMed ID: 16866719 [Abstract] [Full Text] [Related]
16. A randomized trial comparing amitriptyline versus topiramate for the prophylaxis of chronic daily headache in pediatric patients. Sezer T, Kandemir H, Alehan F. Int J Neurosci; 2013 Aug 12; 123(8):553-6. PubMed ID: 23421731 [Abstract] [Full Text] [Related]
17. Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. He A, Song D, Zhang L, Li C. J Headache Pain; 2017 Dec 12; 18(1):26. PubMed ID: 28220376 [Abstract] [Full Text] [Related]